Breaking down the silos between departments opens up an exciting new level of efficiency, cost savings, communication, and faster, more informed decision-making.

• Sea's novel synthetic molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the central nervous system, "the CNS"

  • Two potent, selective, pre-clinical stage molecules are being advanced as possible treatments for three therapeutic indications

• Sea's lead SPM-0404 in investigational new drug-enabling studies for tinnitus, epilepsy, and ALS

  • TCG GreenChem will conduct CMC (Chemistry, Manufacturing, & Controls) development on SPM-0404

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Net Loss and Earnings per Diluted Share of $7.1 million and $1.53

Adjusted EBITDA was a $2.3 million loss, a $1.0 million improvement versus third quarter of 2023

The Company achieved third quarter revenue guidance of $2.0 million, a growth of 325% versus second quarter of 2024

The Company expects to generate $2.4 million in revenue in the fourth quarter of 2024

Stockholders' Equity was $5.8 million at the end of the third quarter of 2024

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial -

- Dermata continues discussions with potential botulinum toxin partners for DMT410 -

- Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 -

Net income of $1.5 million

Adjusted EBITDA¹ of $1.9 million

ADHD Portfolio net revenue up 1% to $15.3 million

Pediatric Portfolio net revenue up 54% sequentially

$20.1 million cash balance at September 30, 2024

Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow

Ryan Selhorn promoted to Chief Financial Officer

Company to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time

Making Veterinary Care More Accessible and Affordable Through Urgent Care-Only Model

Q3 Reimbursements from insurance payors totaled $106,567 an increase of 16.4% sequentially

KindlyMD now provides more than 90% in-network insurance coverage in Utah

Should professionals use bulky recording devices or opt for a compact, wearable solution? The Intelligent Voice Badge offers seamless documentation with cutting-edge AI technology.

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million

• CMTA strengthens its role as the leading force in comprehensive CMT research, forging a new strategic alliance with the Inherited Neuropathy Consortium (INC)
• Together, CMTA and INC are driving research to accelerate the path toward effective treatments for every type of CMT

“Care Anywhere” from CGFNS International now available on major podcast streaming sites 

Being in-network with Aetna and Cigna will now allow Clarity Clinic to expand access to their Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programs, ensuring more individuals receive the high-quality care they need for their recovery journey.

Educational conference focused on diagnosis, research and treatment of rare neuroimmune disorders

Jerry Carter and Mackenzie Laughridge Join to Drive Growth and Expand Virtual Nursing Solutions

The second volume of Integrate™ magazine highlights everything from surgical guides and immediate implant placement to incision line opening and stem cell technology.

Quest International’s Expanded FCA Resources Offer Medical Device OEMs Timely, Reliable Support Amid Rising FDA Recalls

McNamara’s extensive experience in scaling imaging and eClinical companies through organic growth and acquisition strategies brings a wealth of expertise to accelerate Yunu’s life sciences business. 

ASTCT® and CIBMTR® Bring Leading Experts Together to Share Groundbreaking Advancements in Hematopoietic Cell Transplantation, Cellular Therapy and Gene Therapy.

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable disease

Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months

Biomarker analysis confirms immune activation in the tumor microenvironment

Data Presented at Society for Immunotherapy of Cancer on November 8, 2024

Training for the proprietary program is aimed at implementing the latest evidenced-based approaches to dementia care amid the growing numbers of Americans affected.

IRB approval on track as scheduled

Next step is obtaining all regulatory approvals, followed by site initiation visit

VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies

As the country is in the midst of a clinician shortage, Fusion has launched an app that will help connect travel healthcare professionals to facilities across the country needing help. 

The Next Age-Defiers You Haven't Heard of Yet
A giant leap into a new era of body rejuvenation.

• Meet with Modular Medical CEO, Jeb Besser

• Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association

• About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks

• Discover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study

Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million

Iodine Software earned the highest industry client satisfaction ranking for informatics in the competitive mid-RCM market with top customer-rated utilization management, computer-assisted medical documentation, clinical coding and documentation integrity, and proven artificial intelligence tools.

Dr. Naba Sharif set to lead initiatives for enhanced allergy and asthma care for New Jersey residents.

REMORY: Elevate Cognitive Health with Unique Sea Squirt-Derived Plasmalogens. Now in the U.S., this Japanese-Innovated Supplement Combines EPA, DHA, and Omega-3s for Enhanced Memory and Brain Function in Aging Adults. Recognized by Japan as a 'Food with Functional Claims,' REMORY is FDA-Notified, Setting a New Standard in Natural Cognitive Support.